ZDHHC11

Summary

ZDHHC11 (zDHHC palmitoyltransferase 11, HGNC:19158) is a protein-coding gene on chromosome 5p15.33, encoding Palmitoyltransferase ZDHHC11 (Q9H8X9). Endoplasmic reticulum-localized palmitoyltransferase that could catalyze the addition of palmitate onto various protein substrates and be involved in a variety of cellular processes.

Enables signaling adaptor activity. Involved in antiviral innate immune response and positive regulation of defense response to virus by host. Located in endoplasmic reticulum.

Source: NCBI Gene 79844 — RefSeq curated summary.

At a glance

• GWAS associations: 3
• Clinical variants (ClinVar): 143 total — 3 pathogenic
• MANE Select transcript: NM_024786

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:19158
Approved symbol	ZDHHC11
Name	zDHHC palmitoyltransferase 11
Location	5p15.33
Locus type	gene with protein product
Status	Approved
Aliases	ZNF399, FLJ13153
Ensembl gene	ENSG00000188818
Ensembl biotype	protein_coding
Entrez	79844

Gene structure

Transcript identifiers

Ensembl transcripts: 12 — 4 protein_coding, 4 protein_coding_CDS_not_defined, 3 retained_intron, 1 nonsense_mediated_decay

ENST00000283441, ENST00000503758, ENST00000503880, ENST00000505815, ENST00000507800, ENST00000508951, ENST00000511193, ENST00000511539, ENST00000512190, ENST00000512775, ENST00000685990, ENST00000688955

RefSeq mRNA: 2 — MANE Select: NM_024786 NM_001393492, NM_024786

CCDS: CCDS3857

Canonical transcript exons

ENST00000283441 — 13 exons

Exon	Start	End
ENSE00001316958	850381	850986
ENSE00001399989	795605	796580
ENSE00001646042	837365	837480
ENSE00003470064	819525	819612
ENSE00003485145	833773	833807
ENSE00003508915	840495	840650
ENSE00003531690	848482	848660
ENSE00003551627	847514	847615
ENSE00003555795	801100	801164
ENSE00003566052	814761	814795
ENSE00003624085	821861	821895
ENSE00003641339	825164	825251
ENSE00003655036	843600	843724

Expression profiles

Bgee: expression breadth ubiquitous, 251 present calls, max score 98.14.

Top tissues by expression

255 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right uterine tube	UBERON:0001302	98.14	gold quality
cardiac muscle of right atrium	UBERON:0003379	94.86	silver quality
right hemisphere of cerebellum	UBERON:0014890	94.57	gold quality
cerebellar hemisphere	UBERON:0002245	94.15	gold quality
cerebellar cortex	UBERON:0002129	94.09	gold quality
cerebellum	UBERON:0002037	93.51	gold quality
cerebellar vermis	UBERON:0004720	92.76	gold quality
lateral globus pallidus	UBERON:0002476	92.74	gold quality
myocardium	UBERON:0002349	91.79	silver quality
kidney epithelium	UBERON:0004819	91.52	silver quality
cardiac atrium	UBERON:0002081	91.34	gold quality
substantia nigra pars reticulata	UBERON:0001966	91.21	gold quality
pituitary gland	UBERON:0000007	91.19	gold quality
right atrium auricular region	UBERON:0006631	91.14	gold quality
tendon of biceps brachii	UBERON:0008188	90.81	gold quality
lateral nuclear group of thalamus	UBERON:0002736	90.49	gold quality
adenohypophysis	UBERON:0002196	90.38	gold quality
upper arm skin	UBERON:0004263	90.24	silver quality
primary visual cortex	UBERON:0002436	89.90	gold quality
vena cava	UBERON:0004087	89.89	gold quality
right frontal lobe	UBERON:0002810	89.84	gold quality
apex of heart	UBERON:0002098	89.69	gold quality
inferior vagus X ganglion	UBERON:0005363	89.46	gold quality
occipital lobe	UBERON:0002021	89.26	gold quality
subthalamic nucleus	UBERON:0001906	89.17	gold quality
substantia nigra pars compacta	UBERON:0001965	89.16	gold quality
ventral tegmental area	UBERON:0002691	89.13	gold quality
Brodmann (1909) area 9	UBERON:0013540	88.96	gold quality
dorsal plus ventral thalamus	UBERON:0001897	88.76	gold quality
bronchial epithelial cell	CL:0002328	88.74	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	4.22

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

35 targeting ZDHHC11, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-378G	99.71	64.90	1106
HSA-MIR-892A	99.54	68.16	1141
HSA-MIR-4437	99.52	65.29	1266
HSA-MIR-4318	99.38	66.94	1505
HSA-MIR-5580-5P	99.38	66.96	1139
HSA-MIR-6853-3P	99.36	70.79	1558
HSA-MIR-3678-3P	99.31	67.10	1432
HSA-MIR-4254	99.11	65.15	1315
HSA-MIR-4478	99.07	65.16	2320
HSA-MIR-6737-3P	98.95	68.56	1577
HSA-MIR-7157-3P	98.95	68.70	1582
HSA-MIR-5008-3P	98.73	67.50	1433
HSA-MIR-7977	98.65	66.18	2590
HSA-MIR-934	98.49	70.44	581
HSA-MIR-6764-3P	98.44	67.64	1153
HSA-MIR-6824-3P	98.44	67.62	1154
HSA-MIR-6792-5P	98.39	68.16	1330
HSA-MIR-3929	98.32	65.58	1026
HSA-MIR-3132	97.96	67.91	711
HSA-MIR-193B-5P	97.91	65.88	837
HSA-MIR-3661	97.83	67.30	705
HSA-MIR-1278	97.75	67.55	628
HSA-MIR-6855-5P	97.51	66.03	830
HSA-MIR-4797-3P	97.48	67.14	989
HSA-MIR-4693-5P	97.35	67.02	1234
HSA-MIR-7106-3P	97.33	65.33	644
HSA-MIR-4712-5P	97.24	67.79	775
HSA-MIR-770-5P	97.24	68.10	758

Literature-anchored findings (GeneRIF, showing 5)

• data suggest that gain of 5p15.33 (TPPP and ZDHHC11) may become a potential biomarker identifying high-risk patients with disease progression in bladder cancer. (PMID:18025801)
• In silico screening for palmitoyl substrates reveals a role for DHHC1/3/10 (zDHHC1/3/11)-mediated neurochondrin palmitoylation in its targeting to Rab5-positive endosomes. (PMID:23687301)
• First, MYC downregulates miR-150 to unleash MYB from the miR-150-mediated repression. Second, MYC induces ZDHHC11 and ZDHHC11B that further ensures the maintenance of high MYB levels (PMID:28331227)
• ZDHHC11 and ZDHHC11B are novel targets of miR-150 with a key role in maintaining elevated levels of the MYB oncogene required for the high proliferation rate of Burkitt lymphoma cells. (PMID:28331227)
• Circular ZDHHC11 supports Burkitt lymphoma growth independent of its miR-150 binding capacity. (PMID:38627588)

Cross-species orthologs

12 orthologs

Organism	Symbol	Gene ID
danio_rerio	zdhhc11	ENSDARG00000076202
mus_musculus	Zdhhc11	ENSMUSG00000069189
rattus_norvegicus	Zdhhc11	ENSRNOG00000039743
drosophila_melanogaster	Dnz1	FBGN0027453
drosophila_melanogaster	CG1407	FBGN0033474
drosophila_melanogaster	CG17287	FBGN0034202
caenorhabditis_elegans	dhhc-7	WBGENE00007637
caenorhabditis_elegans	dhhc-12	WBGENE00010323
caenorhabditis_elegans	dhhc-2	WBGENE00012948
caenorhabditis_elegans		WBGENE00014075
caenorhabditis_elegans		WBGENE00016620
caenorhabditis_elegans		WBGENE00020066

Paralogs (17): ZDHHC6 (ENSG00000023041), ZDHHC15 (ENSG00000102383), ZDHHC2 (ENSG00000104219), ZDHHC4 (ENSG00000136247), ZDHHC7 (ENSG00000153786), ZDHHC1 (ENSG00000159714), ZDHHC12 (ENSG00000160446), ZDHHC3 (ENSG00000163812), ZDHHC19 (ENSG00000163958), ZDHHC14 (ENSG00000175048), ZDHHC21 (ENSG00000175893), ZDHHC22 (ENSG00000177108), ZDHHC20 (ENSG00000180776), ZDHHC23 (ENSG00000184307), ZDHHC9 (ENSG00000188706), ZDHHC18 (ENSG00000204160), ZDHHC11B (ENSG00000206077)

Protein

Protein identifiers

Palmitoyltransferase ZDHHC11 — Q9H8X9 (reviewed: Q9H8X9)

Alternative names: Zinc finger DHHC domain-containing protein 11, Zinc finger protein 399

All UniProt accessions (4): A0A8I5KQG6, D6RE92, Q9H8X9, H0Y9D0

UniProt curated annotations — full annotation on UniProt →

Function. Endoplasmic reticulum-localized palmitoyltransferase that could catalyze the addition of palmitate onto various protein substrates and be involved in a variety of cellular processes. Has a palmitoyltransferase activity toward NCDN and regulates NCDN association with endosome membranes through this palmitoylation. May play a role in cell proliferation. Also has a palmitoyltransferase activity-independent function in DNA virus-triggered and CGAS-mediated innate immune response. Functions as an adapter that recruits IRF3 to STING1 to promote the activation of that key transcriptional regulator of type I interferon (IFN)-dependent immune response.

Subunit / interactions. Interacts with IRF3 and STING1; in presence of DNA viruses recruits IRF3 to STING1 promoting IRF3 phosphorylation and activation.

Subcellular location. Endoplasmic reticulum membrane.

Tissue specificity. Expressed in testis.

Domain organisation. The DHHC domain is required for palmitoyltransferase activity.

Similarity. Belongs to the DHHC palmitoyltransferase family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9H8X9-1	1	yes
Q9H8X9-2	2

RefSeq proteins (2): NP_001380421, NP_079062* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR001594	Palmitoyltrfase_DHHC	Domain
IPR039859	PFA4/ZDH16/20/ERF2-like	Family

Pfam: PF01529

Catalyzed reactions (Rhea), 1 shown:

• L-cysteinyl-[protein] + hexadecanoyl-CoA = S-hexadecanoyl-L-cysteinyl-[protein] + CoA (RHEA:36683)

UniProt features (24 total): topological domain 5, transmembrane region 4, splice variant 3, sequence variant 3, region of interest 2, compositionally biased region 2, mutagenesis site 2, chain 1, domain 1, active site 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9H8X9-F1	74.62	0.58

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 155 (s-palmitoyl cysteine intermediate)

Mutagenesis-validated functional residues (2):

Position	Phenotype
152–153	no effect on the regulation of sting1-mediated innate immune response.
155	no effect on the regulation of sting1-mediated innate immune response.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-9694548	Maturation of spike protein

MSigDB gene sets: 150 (showing top): GOBP_REGULATION_OF_DEFENSE_RESPONSE_TO_VIRUS, GOBP_LIPOPROTEIN_METABOLIC_PROCESS, GOBP_PROTEIN_TARGETING, GOBP_PEPTIDYL_CYSTEINE_MODIFICATION, GOBP_PROTEIN_TARGETING_TO_MEMBRANE, ONKEN_UVEAL_MELANOMA_UP, GOBP_DEFENSE_RESPONSE_TO_OTHER_ORGANISM, SMID_BREAST_CANCER_LUMINAL_B_UP, BLALOCK_ALZHEIMERS_DISEASE_UP, DELYS_THYROID_CANCER_DN, GOBP_LIPOPROTEIN_BIOSYNTHETIC_PROCESS, GOBP_REGULATION_OF_RESPONSE_TO_STRESS, GOBP_ESTABLISHMENT_OF_PROTEIN_LOCALIZATION_TO_MEMBRANE, NIKOLSKY_BREAST_CANCER_5P15_AMPLICON, GOBP_DEFENSE_RESPONSE_TO_VIRUS

GO Biological Process (4): positive regulation of defense response to virus by host (GO:0002230), protein targeting to membrane (GO:0006612), peptidyl-L-cysteine S-palmitoylation (GO:0018230), antiviral innate immune response (GO:0140374)

GO Molecular Function (6): protein-cysteine S-palmitoyltransferase activity (GO:0019706), signaling adaptor activity (GO:0035591), protein binding (GO:0005515), palmitoyltransferase activity (GO:0016409), transferase activity (GO:0016740), acyltransferase activity (GO:0016746)

GO Cellular Component (6): Golgi membrane (GO:0000139), endoplasmic reticulum (GO:0005783), endoplasmic reticulum membrane (GO:0005789), Golgi apparatus (GO:0005794), endosome membrane (GO:0010008), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Translation of Structural Proteins	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
bounding membrane of organelle	2
cytoplasm	2
endomembrane system	2
intracellular membrane-bounded organelle	2
regulation of defense response to virus by host	1
protein targeting	1
establishment of protein localization to membrane	1
peptidyl-S-diacylglycerol-L-cysteine biosynthetic process from peptidyl-cysteine	1
protein palmitoylation	1
innate immune response	1
defense response to virus	1
palmitoyltransferase activity	1
protein-cysteine S-acyltransferase activity	1
protein-macromolecule adaptor activity	1
binding	1
acyltransferase activity, transferring groups other than amino-acyl groups	1
catalytic activity	1
transferase activity	1
Golgi apparatus	1
organelle membrane	1
nuclear outer membrane-endoplasmic reticulum membrane network	1
endoplasmic reticulum subcompartment	1
endosome	1
cytoplasmic vesicle membrane	1
cellular anatomical structure	1

Protein interactions and networks

STRING

346 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZDHHC11	ZDHHC22	Q8N966	693
ZDHHC11	ZDHHC3	Q9NYG2	645
ZDHHC11	ZDHHC13	Q8IUH4	639
ZDHHC11	ZDHHC23	Q8IYP9	553
ZDHHC11	ZDHHC24	Q6UX98	460
ZDHHC11	PPT1	P50897	428
ZDHHC11	SLC6A18	Q96N87	375
ZDHHC11	ZDHHC2	Q9UIJ5	374
ZDHHC11	TPPP	O94811	368
ZDHHC11	ZDHHC15	Q96MV8	363
ZDHHC11	ZDHHC19	Q8WVZ1	351
ZDHHC11	ZDHHC5	Q9C0B5	349
ZDHHC11	ZDHHC17	Q8IUH5	340
ZDHHC11	ZDHHC8	Q9ULC8	337
ZDHHC11	CCDC198	Q9NVL8	314
ZDHHC11	ZDHHC7	Q9NXF8	314

IntAct

19 interactions, top by confidence:

A	B	Type	Score
ZDHHC11	TMEM14B	psi-mi:“MI:0915”(physical association)	0.560
ZDHHC11	APOB	psi-mi:“MI:0914”(association)	0.530
ZDHHC11	GPR37	psi-mi:“MI:0915”(physical association)	0.370
	ZDHHC11	psi-mi:“MI:0915”(physical association)	0.370
CCL1	ZDHHC11	psi-mi:“MI:0915”(physical association)	0.370
LTA	ZDHHC11	psi-mi:“MI:0915”(physical association)	0.370
ZDHHC11	TSPAN15	psi-mi:“MI:0914”(association)	0.350
ZDHHC11	SRC	psi-mi:“MI:0914”(association)	0.350
ZDHHC11	NRP1	psi-mi:“MI:0914”(association)	0.350
ZDHHC11	TMEM14B	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (36): ZDHHC11 (Two-hybrid), FAM134A (Affinity Capture-MS), KIAA1715 (Affinity Capture-MS), MAPK3 (Affinity Capture-MS), C4orf32 (Affinity Capture-MS), APOB (Affinity Capture-MS), EFNB1 (Affinity Capture-MS), FGFR1 (Affinity Capture-MS), PPM1A (Affinity Capture-MS), GLMN (Affinity Capture-MS), ANKRD13A (Affinity Capture-MS), ZDHHC11 (Two-hybrid), ZDHHC11 (Two-hybrid), KIAA1715 (Affinity Capture-MS), FAM134A (Affinity Capture-MS)

ESM2 similar proteins: A0A0R4IF99, A2A3K4, A7E379, E7EZI4, E7F4Z4, E7FH11, E9QCD3, F1Q7H8, F1QHM7, F1QX91, O36371, O60291, O80685, P0C7U3, Q09282, Q0VD59, Q14AK4, Q28IK8, Q4R7E2, Q4WN54, Q58CU4, Q5BLG4, Q5RA75, Q5T0T0, Q5XH39, Q5Y5T1, Q5Y5T3, Q6C890, Q6DR03, Q6NZQ8, Q6X632, Q76IC6, Q8BQQ1, Q8BQU7, Q8I0G4, Q8IYP9, Q8IZN3, Q8R0N9, Q8TCQ1, Q93227

Diamond homologs: E7EZI4, E7F4Z4, P0C7U3, Q14AK4, Q8R0N9, Q8WTX9, Q9H8X9, Q8L5Y5, A0A0R4IQZ2, A0PK84, A5WVX9, B8A4F0, C8VCL4, E9PTT0, F1QAM1, F1QHM7, F1QX91, O60069, P0CS66, P0CS67, Q03289, Q04629, Q09701, Q10L01, Q2TGI8, Q2TGJ4, Q2TGK3, Q4I8B6, Q4IA62, Q4P6L3, Q4R690, Q4WZL8, Q4X251, Q550R7, Q552M6, Q554E7, Q58DT3, Q59QL0, Q5ADN9, Q5B0V6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

143 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	3
Likely pathogenic	0
Uncertain significance	100
Likely benign	19
Benign	2

Top pathogenic / likely-pathogenic (3)

Variant ID	HGVS	Classification
2427644	NC_000005.9:g.(?482643)(1895829_?)del	Pathogenic
394397	GRCh37/hg19 5p15.33-15.32(chr5:22149-4641409)x1	Pathogenic
814655	GRCh37/hg19 5p15.33-15.32(chr5:113576-5657333)x1	Pathogenic

SpliceAI

3273 predictions. Top by Δscore:

Variant	Effect	Δscore
5:801174:A:C	acceptor_gain	1.0000
5:801179:C:CT	acceptor_gain	1.0000
5:801180:A:T	acceptor_gain	1.0000
5:821852:CAAA:C	donor_gain	1.0000
5:837481:C:CC	acceptor_gain	1.0000
5:840493:A:AC	donor_gain	1.0000
5:840494:C:CC	donor_gain	1.0000
5:840494:CT:C	donor_gain	1.0000
5:843595:CGTA:C	donor_loss	1.0000
5:843596:GTA:G	donor_loss	1.0000
5:843597:TACC:T	donor_loss	1.0000
5:843598:A:AG	donor_loss	1.0000
5:843599:C:CA	donor_loss	1.0000
5:796578:CTC:C	acceptor_gain	0.9900
5:796580:CCT:C	acceptor_loss	0.9900
5:796581:C:CC	acceptor_gain	0.9900
5:796581:CTGC:C	acceptor_loss	0.9900
5:796582:T:A	acceptor_loss	0.9900
5:801174:A:AC	acceptor_gain	0.9900
5:801176:A:C	acceptor_gain	0.9900
5:819626:C:CT	acceptor_gain	0.9900
5:825250:CT:C	acceptor_gain	0.9900
5:837360:GGTA:G	donor_loss	0.9900
5:837361:GTAC:G	donor_loss	0.9900
5:837362:TACCT:T	donor_loss	0.9900
5:837363:A:C	donor_loss	0.9900
5:837364:CCTGG:C	donor_loss	0.9900
5:837403:T:A	donor_gain	0.9900
5:837479:CT:C	acceptor_gain	0.9900
5:837479:CTCT:C	acceptor_loss	0.9900

AlphaMissense

2712 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
5:847564:G:C	F151L	0.999
5:847564:G:T	F151L	0.999
5:847566:A:G	F151L	0.999
5:847577:C:G	C147S	0.999
5:847578:A:T	C147S	0.999
5:847579:C:A	K146N	0.999
5:847579:C:G	K146N	0.999
5:847581:T:C	K146E	0.999
5:847586:C:G	C144S	0.999
5:847586:C:T	C144Y	0.999
5:847587:A:T	C144S	0.999
5:847594:G:C	C141W	0.999
5:847595:C:G	C141S	0.999
5:847596:A:G	C141R	0.999
5:847596:A:T	C141S	0.999
5:847597:G:C	H140Q	0.999
5:847597:G:T	H140Q	0.999
5:847599:G:C	H140D	0.999
5:848494:C:G	C130S	0.999
5:848495:A:T	C130S	0.999
5:848502:G:C	C127W	0.999
5:848503:C:G	C127S	0.999
5:848503:C:T	C127Y	0.999
5:848504:A:G	C127R	0.999
5:848504:A:T	C127S	0.999
5:847529:C:T	G163E	0.998
5:847534:G:C	C161W	0.998
5:847535:C:G	C161S	0.998
5:847536:A:T	C161S	0.998
5:847558:G:C	H153Q	0.998

dbSNP variants (sampled 300 via entrez): RS1000061653 (5:850033 A>G), RS1000078755 (5:861801 T>C), RS1000100803 (5:836337 A>C,G), RS1000260627 (5:821409 G>A), RS1000491909 (5:810318 C>A,G,T), RS1000595979 (5:795672 T>C), RS1000715083 (5:851258 G>A), RS1000767242 (5:851353 G>A), RS1000821461 (5:809406 A>G), RS1000914359 (5:852741 C>A,T), RS1000994876 (5:849126 C>A), RS1001180497 (5:833804 C>T), RS1001206345 (5:816024 T>A,C), RS1001384803 (5:839809 C>A,T), RS1001507423 (5:831444 G>A)

Disease associations

OMIM: gene `` | disease phenotypes: MIM:189800, MIM:613989

GenCC curated gene-disease

Mondo (3): preeclampsia (MONDO:0005081), dyskeratosis congenita, autosomal dominant 2 (MONDO:0013521), idiopathic pulmonary fibrosis (MONDO:0800504)

Orphanet (2): Preeclampsia (Orphanet:275555), Idiopathic pulmonary fibrosis (Orphanet:2032)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

3 associations (top):

Study	Trait	p-value
GCST002553_8	Pancreatic cancer	1.000000e-13
GCST004749_105	Lung cancer in ever smokers	4.000000e-06
GCST90020029_1127	Waist circumference adjusted for body mass index	7.000000e-09

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007789	BMI-adjusted waist circumference

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D054990	Idiopathic Pulmonary Fibrosis	C08.381.483.652.500
D011225	Pre-Eclampsia	C12.050.703.395.249

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

40 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
sodium arsenite	decreases expression, affects cotreatment, increases abundance, increases expression	4
Benzo(a)pyrene	affects methylation, decreases expression	3
bisphenol A	increases expression, affects cotreatment, decreases methylation	2
Arsenic	affects cotreatment, decreases expression, increases abundance, affects methylation	2
aristolochic acid I	increases expression	1
trichostatin A	increases expression	1
beta-lapachone	decreases expression	1
sulforaphane	increases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
cobaltous chloride	decreases expression	1
perfluorooctanoic acid	decreases expression	1
manganese chloride	affects cotreatment, decreases expression, increases abundance	1
1-nitropyrene	increases expression	1
di-n-butylphosphoric acid	affects expression	1
ICG 001	increases expression	1
NSC 689534	affects binding, increases expression	1
Fulvestrant	decreases methylation, affects cotreatment	1
Leflunomide	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Copper	affects binding, increases expression	1
Dichlorodiphenyl Dichloroethylene	decreases expression	1
Doxorubicin	affects response to substance	1
Etoposide	affects response to substance	1
Formaldehyde	increases expression	1
Hydrogen Peroxide	affects expression	1
Manganese	affects cotreatment, decreases expression, increases abundance	1
Progesterone	decreases expression	1
Silicon Dioxide	increases expression	1
Theophylline	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 cancer cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_TY63	HAP1 ZDHHC11 (-) 1	Cancer cell line	Male
CVCL_TY64	HAP1 ZDHHC11 (-) 2	Cancer cell line	Male

Clinical trials (associated diseases)

300 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00117546	PHASE4	UNKNOWN	Cardiovascular and Autonomic Reactivity in Women With a History of Pre-eclampsia
NCT00567957	PHASE4	UNKNOWN	Remifentanil for General Anesthesia in Preeclamptics
NCT01030627	PHASE4	COMPLETED	Treatment Approaches to Preeclampsia
NCT01352234	PHASE4	COMPLETED	Comparison of Doses of Acetylsalicylic Acid in Women With Previous History of Preeclampsia
NCT01361425	PHASE4	UNKNOWN	Anti-Hypertensive Treatment In Stable Pregnant Women With Severe Pre-Eclampsia (Metildopape)
NCT01729468	PHASE4	COMPLETED	Prevention of Pre-eclampsia and SGA by Low-Dose Aspirin in Nulliparous Women With Abnormal First-trimester Uterine Artery Dopplers
NCT01761916	PHASE4	COMPLETED	Clonidine Versus Captopril for Treatment of Postpartum Very High Blood Pressure
NCT01912677	PHASE4	COMPLETED	Oral Antihypertensive Regimens for Management of Hypertension in Pregnancy
NCT02025426	PHASE4	TERMINATED	Phenylephrine Versus Ephedrine in Pre-eclampsia
NCT02091401	PHASE4	COMPLETED	A Trial Comparing Treatment With the Springfusor Infusion Pump to the IV Magnesium Sulfate Regimen
NCT02163655	PHASE4	COMPLETED	Diuretics for Postpartum High Blood Pressure in Preeclampsia
NCT02338687	PHASE4	COMPLETED	Low Dose Calcium to Prevent Preeclampsia
NCT02396030	PHASE4	TERMINATED	Different Schemes of Magnesium Sulfate for Preeclampsia
NCT02531490	PHASE4	UNKNOWN	Early Vascular Adjustments During Hypertensive Pregnancy
NCT02699827	PHASE4	COMPLETED	Adding MgSO4 to Epidural Levobupivacaine in CS for Patients With Preeclampsia
NCT02835339	PHASE4	COMPLETED	Magnesium Sulfate in Obese Preeclamptics
NCT02891174	PHASE4	COMPLETED	The Effect of Ibuprofen on Post-partum Blood Pressure in Women With Hypertensive Disorders of Pregnancy
NCT02911701	PHASE4	COMPLETED	Effect of Acetaminophen on Postpartum Blood Pressure Control in Preeclampsia With Severe Features
NCT03171480	PHASE4	COMPLETED	Use of Nitrous Oxide Donor for Labor Induction in Women With PreEclampsia
NCT03233880	PHASE4	UNKNOWN	Impact of Antichlamydial Treatment on the Rate of Preeclampsia
NCT03237000	PHASE4	UNKNOWN	Effect of Administering Intravenous Magnesium Sulfate on Fetal Cardiotocography and Neonatal Outcome in Preeclamptic Patients
NCT03506724	PHASE4	COMPLETED	Response to Anti-hypertensives in Pregnant and Postpartum Patients
NCT03674606	PHASE4	COMPLETED	Trial of Early Screening Test for Pre-eclampsia and Growth Restriction
NCT03735433	PHASE4	TERMINATED	The Effect of Two Aspirin Dosing Strategies for Obese Women at High Risk for Preeclampsia
NCT03824119	PHASE4	UNKNOWN	Postpartum NSAIDS and Maternal Hypertension
NCT04051567	PHASE4	UNKNOWN	Low-dose Aspirin for Prevention of Adverse Pregnancy Outcomes in Twin Pregnancies
NCT04077853	PHASE4	COMPLETED	Progesterone in Expectantly Managed Early-onset Preeclampsia
NCT04158830	PHASE4	WITHDRAWN	Aspirin (ASA) Therapy and Preeclampsia Prevention
NCT04424693	PHASE4	UNKNOWN	Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36
NCT04631627	PHASE4	UNKNOWN	Early Prediction and Randomised Prevention of Preeclampsia With Low Dose Aspirin in Chinese Cohort
NCT04656665	PHASE4	UNKNOWN	The Effectiveness of Aspirin on Preventing Pre-eclampsia
NCT04797949	PHASE4	WITHDRAWN	Adherence to Universal Aspirin Compared to Screening Indicated Aspirin for Prevention of Preeclampsia
NCT04908982	PHASE4	UNKNOWN	Aspirin for the Prevention of Preeclampsia in Women With Stage 1 Hypertension
NCT05221164	PHASE4	UNKNOWN	162 mg of Aspirin for Prevention of Preeclampsia
NCT05294952	PHASE4	UNKNOWN	co Ihibtory Receptor in Preeclampsia
NCT05514847	PHASE4	ACTIVE_NOT_RECRUITING	Low Dose Aspirin for Preterm Preeclampsia Preventionmg/day Dose in High-risk Patients
NCT05586373	PHASE4	COMPLETED	Ibuprofen vs Dipyrone After C-section in Preeclampsia
NCT06069102	PHASE4	COMPLETED	Optimal Blood Pressure Treatment Thresholds Postpartum
NCT06107335	PHASE4	NOT_YET_RECRUITING	Effect of Albumin Versus Routine Care on Hemodynamic Response and Stability in Patients With Preeclampsia Guided by a Non-invasive Hemodynamic Monitoring System During Cesarean Delivery With Spinal Anesthesia
NCT06281665	PHASE4	RECRUITING	Treatment With Aspirin After Preeclampsia: TAP Trial